Key result
Patients with NSTEMI were less likely to receive evidence-based medications than those with STEMI, despite high in-hospital mortality in both groups (12.5% vs 14.3%).
Why the study?
Are evidence-based medications and lifestyle modification interventions used differently in patients with NSTEMI compared to STEMI?
Observational (n=185,968)
Yes
Are evidence-based medications and lifestyle modification interventions used differently in patients with NSTEMI compared to STEMI?
Absolute Event Rate: 12.5% vs 14.3%
Evidence-based therapies are significantly underutilized in NSTEMI compared to STEMI patients, highlighting a critical gap in quality of care that needs addressing to improve outcomes.
No takes yet. Share an insight, caveat, or question.
NSTEMI patients receive fewer guideline-recommended therapies than STEMI; challenges assumptions of equivalent care quality and leaves open targeted improvement efforts.
Matthew T. Roe (2005) conducted an observational in Acute myocardial infarction (STEMI and NSTEMI) (n=185,968). NSTEMI vs. STEMI was evaluated on In-hospital mortality. Patients with NSTEMI were less likely to receive evidence-based medications than those with STEMI, despite high in-hospital mortality in both groups (12.5% vs 14.3%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: